<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030458</url>
  </required_header>
  <id_info>
    <org_study_id>NOAAH version 5.0.2</org_study_id>
    <nct_id>NCT01030458</nct_id>
  </id_info>
  <brief_title>Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial</brief_title>
  <acronym>NOAAH</acronym>
  <official_title>Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kinshasa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yaounde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Yaounde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Libreville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cardiology Abidjan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ilorin Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nigeria, Enugu Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Aristide Le Dantec, Dakar, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the blood pressure lowering efficacy of a treatment
      regimen based on a dihydropyridine calcium-channel blocker combined with an angiotensin II
      type-1 receptor blocker with the recommended treatment regimen based on a low-dose thiazide
      diuretic combined with a beta-blocker.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:

      Sitting systolic blood pressure (average of three readings) will be the primary outcome
      variable.

      Secondary

        1. To compare the time interval between the two treatment groups, which after randomisation
           will be required, to reach and maintain the target defined as a blood pressure below 140
           mm Hg systolic and 90 mm Hg diastolic;

        2. To compare the duration of follow-up, during which a steady blood pressure control will
           be achieved;

        3. To evaluate the incidence of adverse events, symptoms, biochemical abnormalities and ECG
           changes in the two treatment groups;

        4. To assess the adherence to antihypertensive treatment as well as the rate of drop-outs
           in both treatment arms during a six-month period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sitting Systolic Blood Pressure on Automated Measurement</measure>
    <time_frame>6 months follow-up after randomization</time_frame>
    <description>Blood pressure is measured by means of validated oscillometric OMRON 705IT recorders (OMRON Healthcare Europe BV, Nieuwegein, Netherlands), after the patient has been seated for 5 minutes in a quiet room, according to the ESC/ESH guidelines. Three consecutive blood pressure readings are obtained and the average of these 3 measurements is used as the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Blood Pressure Control</measure>
    <time_frame>6 months follow-up after randomization</time_frame>
    <description>The time (in weeks) after randomisation that will be required to reach and maintain the target, defined as a blood pressure below 140 mmHg systolic and 90 mmHg diastolic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects to Study Medications</measure>
    <time_frame>6 months follow-up after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Reaching Blood Pressure Control at the End of Follow-up</measure>
    <time_frame>6 months follow-up after randomization</time_frame>
    <description>This variable gives the proportion of patients reaching blood pressure control over time (&lt; 140 mmHg systolic and &lt; 90 mmHg diastolic)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>amlodipine plus valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrochlorothiazide plus bisoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine 5/10 mg per day plus valsartan 160 mg/day</intervention_name>
    <description>Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning</description>
    <arm_group_label>amlodipine plus valsartan</arm_group_label>
    <other_name>ExForge®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day</intervention_name>
    <description>hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning</description>
    <arm_group_label>hydrochlorothiazide plus bisoprolol</arm_group_label>
    <other_name>Lodoz®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women or men within an age range from 30 to 69 years with uncomplicated hypertension.

          -  Blood pressure measured in the sitting position after at least 5 minutes rest (average
             of three readings at the last run-in-visit) should range from 140 to 179 mm Hg
             systolic or from 90 to 109 mm Hg diastolic (grades 1 or 2 of hypertension). Patients
             must have uncomplicated hypertension with a maximum of two additional risk factors, as
             defined in the 2007 guidelines of the European Societies of Hypertension and
             Cardiology.

          -  Systolic blood pressure in the upright position must be at least 110 mm Hg (mean of
             three readings obtained immediately after the patient has assumed a standing
             position).

          -  Patients who have never been treated for hypertension or in whom previous
             antihypertensive drug treatment has been discontinued for at least four weeks before
             the last run-in visit can be randomised. If two weeks after discontinuation of
             previous antihypertensive treatment the blood pressure is higher than 160 mm Hg
             systolic or higher than 100 mm Hg diastolic and if the patient has complaints, the
             patient can be randomised immediately to active blood pressure lowering treatment with
             either the newer or older antihypertensive drugs.

          -  The patient must provide informed written consent.

        Exclusion Criteria:

          -  Premenopausal women not applying anticonception.

          -  A history of cardiovascular disease.

          -  Secondary hypertension.

          -  Electrocardiographic left ventricular hypertrophy.

          -  More than two cardiovascular risk factors in addition to hypertension.

          -  Diabetes mellitus.

          -  Renal dysfunction.

          -  Recent treatment with two or more antihypertensive drugs or a contra-indication to
             discontinue blood pressure lowering agents for 4 weeks.

          -  Severe non-cardiovascular disease.

          -  Known contra indications for the first-line study medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Kingue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Général de Yaoundé, BP 5408, Yaoundé, Cameroun</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Lemogoum, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Douala, Douala, Cameroon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Mipinda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Central Universitaire de Libreville, Libreville, Gabon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omotoso Babatunde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ilorin, Ilorin, Nigeria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ifeoma E Ulasi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Enugu, Enugu, Nigeria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serigne Abdou Ba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Aristide Le Dantec, Dakar, Sénégal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-René M'Buyamba-Kabangu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Kinshasa, Kinshasa, Democratic Republic of Congo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan A Staessen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Leuven, Leuven, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ecole de Médecine de Douala</name>
      <address>
        <city>Douala</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Général de Yaoundé</name>
      <address>
        <city>Yaoundé</city>
        <zip>BP 5408</zip>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie d'Abidjan</name>
      <address>
        <city>Abidjan</city>
        <zip>BP V 206</zip>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Central Universitaire de Libreville</name>
      <address>
        <city>Libreville</city>
        <zip>BP 4908</zip>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Enugu</name>
      <address>
        <city>Enugu</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ilorin</name>
      <address>
        <city>Ilorin</city>
        <zip>PMB 1515</zip>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Aristide Le Dantec</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>Côte D'Ivoire</country>
    <country>Gabon</country>
    <country>Nigeria</country>
    <country>Senegal</country>
  </location_countries>
  <link>
    <url>http://www.unikin.cd</url>
    <description>University of Kinshasa</description>
  </link>
  <reference>
    <citation>Odili AN, Richart T, Thijs L, Kingue S, Boombhi HJ, Lemogoum D, Kaptue J, Kamdem MK, Mipinda JB, Omotoso BA, Kolo PM, Aderibigbe A, Ulasi II, Anisiuba BC, Ijoma CK, Ba SA, Ndiaye MB, Staessen JA, M'buyamba-Kabangu JR; NOAAH Investigators. Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial. Blood Press. 2011 Oct;20(5):256-66. doi: 10.3109/08037051.2011.572614. Epub 2011 Apr 15.</citation>
    <PMID>21495829</PMID>
  </reference>
  <results_reference>
    <citation>M'Buyamba-Kabangu JR, Anisiuba BC, Ndiaye MB, Lemogoum D, Jacobs L, Ijoma CK, Thijs L, Boombhi HJ, Kaptue J, Kolo PM, Mipinda JB, Osakwe CE, Odili A, Ezeala-Adikaibe B, Kingue S, Omotoso BA, Ba SA, Ulasi II, Staessen JA; Newer versus Older Antihypertensive Agents in African Hypertensive Patients Trial (NOAAH) Investigators. Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa. J Hum Hypertens. 2013 Dec;27(12):729-35. doi: 10.1038/jhh.2013.56. Epub 2013 Jun 27.</citation>
    <PMID>23803591</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>September 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2013</results_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Jan A. Staessen</investigator_full_name>
    <investigator_title>Professor of Medicine, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Blood pressure</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Blacks</keyword>
  <keyword>Africa</keyword>
  <keyword>Blood pressure control</keyword>
  <keyword>Side-effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine Plus Valsartan</title>
          <description>In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and to achieve blood pressure control, the study medication could be up-titrated to amlodipine 10 mg plus 160 mg valsartan. Patients take the study medication once a day, in the morning. Follow-up visits will take place at 2 weeks, 1 month and every month thereafter, up until 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Hydrochlorothiazide Plus Bisoprolol</title>
          <description>In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg and to achieve blood pressure control, the study medication could be up-titrated to 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol. Patients take the study medication once a day, in the morning. Follow-up visits will take place at 2 weeks, 1 month and every month thereafter, up until 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Logistical reasons</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved or changed job</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Side effect of medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amlodipine Plus Valsartan</title>
          <description>In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.</description>
        </group>
        <group group_id="B2">
          <title>Hydrochlorothiazide Plus Bisoprolol</title>
          <description>In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="9.3"/>
                    <measurement group_id="B2" value="51.2" spread="8.7"/>
                    <measurement group_id="B3" value="51.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Nigeria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Senegal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gabon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cameroon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sitting Systolic Blood Pressure on Automated Measurement</title>
        <description>Blood pressure is measured by means of validated oscillometric OMRON 705IT recorders (OMRON Healthcare Europe BV, Nieuwegein, Netherlands), after the patient has been seated for 5 minutes in a quiet room, according to the ESC/ESH guidelines. Three consecutive blood pressure readings are obtained and the average of these 3 measurements is used as the primary outcome.</description>
        <time_frame>6 months follow-up after randomization</time_frame>
        <population>The main analysis included all randomised patients with at least one follow-up visit, according to the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Plus Valsartan</title>
            <description>In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide Plus Bisoprolol</title>
            <description>In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol</description>
          </group>
        </group_list>
        <measure>
          <title>Sitting Systolic Blood Pressure on Automated Measurement</title>
          <description>Blood pressure is measured by means of validated oscillometric OMRON 705IT recorders (OMRON Healthcare Europe BV, Nieuwegein, Netherlands), after the patient has been seated for 5 minutes in a quiet room, according to the ESC/ESH guidelines. Three consecutive blood pressure readings are obtained and the average of these 3 measurements is used as the primary outcome.</description>
          <population>The main analysis included all randomised patients with at least one follow-up visit, according to the intention-to-treat principle.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.2" spread="10.7"/>
                    <measurement group_id="O2" value="134.1" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Blood Pressure Control</title>
        <description>The time (in weeks) after randomisation that will be required to reach and maintain the target, defined as a blood pressure below 140 mmHg systolic and 90 mmHg diastolic.</description>
        <time_frame>6 months follow-up after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Plus Valsartan</title>
            <description>In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide Plus Bisoprolol</title>
            <description>In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Blood Pressure Control</title>
          <description>The time (in weeks) after randomisation that will be required to reach and maintain the target, defined as a blood pressure below 140 mmHg systolic and 90 mmHg diastolic.</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O2" value="18" lower_limit="4" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side-effects to Study Medications</title>
        <time_frame>6 months follow-up after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Plus Valsartan</title>
            <description>In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide Plus Bisoprolol</title>
            <description>In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol</description>
          </group>
        </group_list>
        <measure>
          <title>Side-effects to Study Medications</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Reaching Blood Pressure Control at the End of Follow-up</title>
        <description>This variable gives the proportion of patients reaching blood pressure control over time (&lt; 140 mmHg systolic and &lt; 90 mmHg diastolic)</description>
        <time_frame>6 months follow-up after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Plus Valsartan</title>
            <description>In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide Plus Bisoprolol</title>
            <description>In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Reaching Blood Pressure Control at the End of Follow-up</title>
          <description>This variable gives the proportion of patients reaching blood pressure control over time (&lt; 140 mmHg systolic and &lt; 90 mmHg diastolic)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O2" value="40" lower_limit="4" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amlodipine Plus Valsartan</title>
          <description>In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.</description>
        </group>
        <group group_id="E2">
          <title>Hydrochlorothiazide Plus Bisoprolol</title>
          <description>In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral leg oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia/asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Jan A Staessen</name_or_title>
      <organization>University of Leuven</organization>
      <phone>+32 16 34 7104</phone>
      <email>jan.staessen@med.kuleuven.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

